Therefore, in the future IL-6 (such as selective inhibition of IL-6 trans-signaling) can be targeted as a potential therapeutic option for treating obesity and metabolic disorders (affecting adipose tissue and impairments of skeletal muscle glucose uptake) as well as for autoimmune and inflammatory conditions. The gene discussed is IL6; the disease is obesity due to melanocortin 4 receptor deficiency.